Skip to content
TrialScanner

NCT04432857

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Phase 1Unknown statusANLLeadMRKCollaborator

Registry record

Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Conditions
Triple-negative Breast Cancer; NSCLC, Squamous or Non-Squamous; Urothelial Carcinoma of the Bladder; Microsatellite Stable (MSS) Colorectal Cancer (CRC); Cervical Cancer
Primary completion
May 31, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04432857 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04432857: AN0025 and Pembrolizumab... | TrialScanner